Alpha-synuclein seed amplification assay longitudinal outcomes in Lewy body disease spectrum
Evidence from neuropathological cohorts indicates that a CSF α-synuclein (α-syn) seed amplification assay (SAA) might provide quantitative kinetic parameters correlating with α-syn pathology burden in patients with Lewy body disease (LBD). Studies are needed to assess their longitudinal trend during the presymptomatic and clinical disease phases and their correlation with measures of disease progr
